Skip to content
TrialScanner

NCT06677190

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Phase 2Active, not recruitingMRKCollaborator

Registry record

Lead sponsor
Dana-Farber Cancer Institute
Conditions
Ovarian Cancer; Ovarian Carcinoma; Endometrial Cancer; Uterine Cancer; Cervical Cancer
Primary completion
Dec 31, 2027Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT06677190 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

3 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT06677190: Belzutifan in Recurrent... | TrialScanner